keyword
MENU ▼
Read by QxMD icon Read
search

non-small cell lung carcinoma

keyword
https://www.readbyqxmd.com/read/27923629/prognostic-value-of-rare-and-complex-mutations-in-egfr-and-serum-levels-of-soluble-egfr-and-its-ligands-in-iranian-non-small-cell-lung-carcinoma-patients
#1
Seyyed Mortaza Haghgoo, Adnan Khosravi, Esmaeil Mortaz, Mihan Pourabdollah Toutkaboni, Sharareh Seifi, Siamak Sabour, Abdolamir Allameh
BACKGROUND: A number of complex and rare mutations in epidermal growth factor receptor (EGFR) gene have been identified and the clinical implication of serum EGFR ligands has also been reported. However, the prognostic significance of these mutations and also the serum EGFR and its ligands in Non-Small Cell Lung Carcinoma (NSCLC) has remained a challenging issue. This study is aimed at finding the prognostic importance of EGFR rare mutations and serum EGFR, amphiregulin (AR), and TGF-α (Transforming Growth Factor-alpha) in NSCLC...
December 3, 2016: Clinical Biochemistry
https://www.readbyqxmd.com/read/27922336/abscopal-regression-following-sabr-for-non-small-cell-lung-cancer-a-case-report
#2
Yang Cong, Ge Shen, Shikai Wu, Ruimin Hao
Out-of-field tumor response, which is also called abscopal effect, bystander effect, or non-target effect, can be regarded as localized irradiation induced systemic antitumorigenic effects, indicating shrinkage of a tumor distant from the irradiated site. Although abscopal effect has been documented in several tumor types, it is a very rare phenomenon which is clinically reported in non-small-cell-lung carcinoma (NSCLC). Herein, we represent a rare case of patient with NSCLC with two lesions in the upper lobe of left lung who, after receiving stereotactic ablative radiation therapy (SABR) to one of the tumors, had an apparent spontaneous regression of the other mass in the lung, suggestive of a radiation-induced abscopal effect...
December 6, 2016: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/27920206/activation-of-d2-dopamine-receptors-in-cd133-ve-cancer-stem-cells-in-non-small-cell-lung-carcinoma-inhibits-proliferation-clonogenic-ability-and-invasiveness-of-these-cells
#3
Soumyabrata Roy, Kai Lu, Mukti Kant Nayak, Avishek Bhuniya, Tithi Ghosh, Suman Kundu, Sarbari Ghosh, Rathindranath Baral, Partha Sarathi Dasgupta, Sujit Basu
Lung carcinoma is the leading cause of cancer-related death worldwide, and among this cancer, non-small cell lung carcinoma (NSCLC) comprises the majority of cases. Furthermore, recurrence and metastasis of NSCLC correlate well with CD133+ve tumor cells, a small population of tumor cells, which has been designated as cancer stem cells (CSC). We here for the first time have demonstrated high expression of D2 dopamine (DA) receptors in CD133+ve adenocarcinoma NSCLC cells. Also, activation of D2 DA receptors in these cells significantly inhibited their proliferation, clonogenic ability and invasiveness by suppressing extracellular-signal-regulated kinases 1/2 (ERK1/2) and AKT, downregulation of octamer-binding transcription factor 4 (Oct-4) expression and matrix metalloproteinase-9 (MMP-9) secretion by these cells...
December 5, 2016: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/27919975/long-term-high-quality-survival-with-single-agent-mifepristone-treatment-despite-advanced-cancer
#4
Jerome H Check, Diane Check, Carrie Wilson, Patrice Lofberg
CASE REPORT: We show long-term high-quality survival following single-agent treatment with a progesterone receptor antagonist in two cases of advanced metastatic cancer. Because no biopsy was performed (patient refused) the exact type of lung cancer was not determined but the majority of oncologists who evaluated the patient thought that the rapid onset and syndrome of inappropriate anti-diuretic hormone was more consistent with small-cell lung cancer. The US Food and Drug Association granted a compassionate-use investigational new drug approval for use of single-agent 200 mg mifepristone orally/day to a moribund woman with never-treated metastatic lung cancer and a male with bilateral renal cell carcinoma who had undergone only a unilateral hemi-nephrectomy...
December 2016: Anticancer Research
https://www.readbyqxmd.com/read/27919952/molecular-factors-associated-with-pemetrexed-sensitivity-according-to-histological-type-in-non-small-cell-lung-cancer
#5
Tsukihisa Yoshida, Tatsuro Okamoto, Tokujiro Yano, Kazuki Takada, Mikihiro Kohno, Kenichi Suda, Mitsuhiro Takenoyama, Yoshinao Oda, Yoshihiko Maehara
BACKGROUND: This study was designed to investigate potential molecules that predict chemosensitivity to pemetrexed (Alimta®) in surgically resected non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Chemosensitivity to ALM and other drugs was assessed by succinate dehydrogenase inhibition (SDI) test in 69 NSCLC samples (55 adenocarcinomas, and 14 squamous cell carcinomas). The mRNA expression levels of Alimta®-target enzymes [thymidylate synthase (TYMS); dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT)], Alimta®-metabolizing enzymes [γ-glutamyl hydrase (GGH) and folylpolyglutamate synthase] and an Alimta® transporter [reduce folate carrier (RFC)] were measured and examined for potential correlations to chemosensitivity...
December 2016: Anticancer Research
https://www.readbyqxmd.com/read/27918099/mir-193b-mediates-cebpd-induced-cisplatin-sensitization-through-targeting-ets1-and-cyclin-d1-in-human-urothelial-carcinoma-cells
#6
Siao-Ren Lin, Hsin-Chih Yeh, Wei-Jan Wang, Hung-Lung Ke, Hui-Hui Lin, Wei-Chi Hsu, Shi-Yi Chao, Tzyh-Chyuan Hour, Wen-Jeng Wu, Yeong-Shiau Pu, A-Mei Huang
Transcription factor CCAAT/enhancer-binding protein delta (CEBPD) plays multiple roles in tumor progression. Studies have demonstrated that cisplatin (CDDP) induced CEBPD expression and had led to chemotherapeutic drug resistance. However, the underlying molecular mechanisms of CDDP-regulated CEBPD expression and its relevant roles in CDDP responses remain elusive. MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression in a sequence-specific manner. Abnormal miRNAs expression is associated with tumor progression...
December 5, 2016: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/27917873/dose-biomarker-response-modeling-of-the-anticancer-effect-of-ethaselen-in-a-human-non-small-cell-lung-cancer-xenograft-mouse-model
#7
Suo-Fu Ye, Jian Li, Shuang-Min Ji, Hui-Hui Zeng, Wei Lu
Thioredoxin reductase (TrxR) is a component of several redox-sensitive signaling cascades that mediate important biological processes such as cell survival, maturation, growth, migration and inhibition of apoptosis. The expression levels of TrxR1 in some human carcinoma cell lines are nearly 10 times higher than those in normal cells. Ethaselen is a novel antitumor candidate that exerts potent inhibition on non-small cell lung cancer (NSCLC) by targeting TrxR. In this study we explored the relationship between the ethaselen dose and TrxR activity level and the relationship between TrxR degradation and tumor apoptosis in a human lung carcinoma A549 xenograft model...
December 5, 2016: Acta Pharmacologica Sinica
https://www.readbyqxmd.com/read/27913776/necitumumab-for-the-treatment-of-squamous-cell-non-small-cell-lung-cancer
#8
Jessica K Brinkmeyer, Donald C Moore
Non-small cell lung cancer is the most common form of lung cancer, accounting for about 85% of all cases and is further subdivided into adenocarcinoma, squamous cell, and large cell carcinoma. Necitumumab (Portrazza™, Eli Lilly and Company) is an anti-epidermal growth factor receptor monoclonal antibody approved for the first-line treatment of squamous cell non-small cell lung cancer in combination with cisplatin and gemcitabine. The safety and efficacy of necitumumab has been evaluated in two-phase III clinical trials, one demonstrating a lack of efficacy in non-squamous non-small cell lung cancer and another demonstrating improvement in overall survival and progression-free survival in squamous cell non-small cell lung cancer...
December 2, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27908620/location-matters-stage-i-non-small-cell-carcinomas-of-the-lower-lobes-treated-with-stereotactic-body-radiation-therapy-are-associated-with-poor-outcomes
#9
Narek Shaverdian, Darlene Veruttipong, Jason Wang, Patrick Kupelian, Michael Steinberg, Percy Lee
INTRODUCTION: The lung is a heterogeneous organ with relative overperfusion of the lung bases. We determined whether a lower lobe primary tumor location was associated with poor outcomes in the setting of stage I non-small-cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT). PATIENTS AND METHODS: The data from consecutive patients with stage I NSCLC treated from 2009 to 2014 with curative intent SBRT were analyzed. Primary tumors in the right and left lower lobes were compared against the tumors in all other locations to determine whether a lower lobe location was associated with worse local, regional, and distant control and worse relapse-free and overall survival...
October 28, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27903989/repression-of-yap-by-nctd-disrupts-nsclc-progression
#10
Jiwei Guo, Yan Wu, Lijuan Yang, Jing Du, Kaikai Gong, Weiwei Chen, Juanjuan Dai, XueLin Li, Sichuan Xi
The efficacy of available lung cancer therapeutic interference is significantly limited by various resistance mechanisms to those drugs. Activation of the oncogene YAP underlying the initiation, progression, and metastasis of lung cancer associates with poor prognosis and confers drug resistance against targeted therapy. In this study, we evaluated the specificity of norcantharidin (NCTD) in repressing YAP to inhibit non-small cell lung carcinoma (NSCLC) progression. Our study revealed that YAP signal pathways were aberrantly activated in lung cancer tissues and cells which rendered more proliferative and invasive phenotypes to human lung cancer cells...
November 26, 2016: Oncotarget
https://www.readbyqxmd.com/read/27903179/gamma-knife-radiosurgery-for-brain-metastases-from-pulmonary-large-cell-neuroendocrine-carcinoma-a-japanese-multi-institutional-cooperative-study-jlgk1401
#11
Takuya Kawabe, Masaaki Yamamoto, Yasunori Sato, Shoji Yomo, Takeshi Kondoh, Osamu Nagano, Toru Serizawa, Takahiko Tsugawa, Hisayo Okamoto, Atsuya Akabane, Kazuyasu Aita, Manabu Sato, Hidefumi Jokura, Jun Kawagishi, Takashi Shuto, Hideya Kawai, Akihito Moriki, Hiroyuki Kenai, Yoshiyasu Iwai, Masazumi Gondo, Toshinori Hasegawa, Soichiro Yasuda, Yasuhiro Kikuchi, Yasushi Nagatomo, Shinya Watanabe, Naoya Hashimoto
OBJECTIVE In 1999, the World Health Organization categorized large cell neuroendocrine carcinoma (LCNEC) of the lung as a variant of large cell carcinoma, and LCNEC now accounts for 3% of all lung cancers. Although LCNEC is categorized among the non-small cell lung cancers, its biological behavior has recently been suggested to be very similar to that of a small cell pulmonary malignancy. The clinical outcome for patients with LCNEC is generally poor, and the optimal treatment for this malignancy has not yet been established...
December 2016: Journal of Neurosurgery
https://www.readbyqxmd.com/read/27901471/esculetin-exerts-anti-proliferative-effects-against-non-small-cell-lung-carcinoma-by-suppressing-specificity-protein-1-in-vitro
#12
Ra H Lee, Young-Joo Jeon, Jin H Cho, Jeong-Yun Jang, Il-Keun Kong, Seok-Ho Kim, MinSeok S Kim, Hak-Jae Chung, Keon B Oh, Seon-Min Park, Jae-Cheon Shin, Jae-Min Seo, Sungho Ko, Jung-Hyun Shim, Jung-Il Chae
Esculetin, a coumarin derivative, is a phenolic compound isolated from Artemisia capillaris, Citrus limonia, and Euphorbia lathyris. Although it has been reported to have anti-inflammatory, anti-oxidant, and anti-proliferative activities in several human cancers, its anti-proliferative activity against non-small-cell lung carcinoma (NSCLC) and the molecular mechanisms involved have not been adequately elucidated. In this study, we used two NSCLC cell lines (NCI-H358 and NCI-H1299) to investigate the anti-proliferative activity and apoptotic effect of esculetin...
November 30, 2016: General Physiology and Biophysics
https://www.readbyqxmd.com/read/27900059/expression-and-survival-significance-of-b-cell-specific-moloney-murine-leukemia-virus-integration-site-1-and-matrix-metalloproteinase-9-in-non-small-cell-lung-cancer
#13
Mingkui Mu, Yang Song, Bin Zhang
One of the main challenges in lung cancer research is identifying patients at high risk of progression and metastasis following surgical resection. In the present study, the prognostic significance of B-cell-specific Moloney murine leukemia virus integration site 1 (BMI1) and matrix metalloproteinase-9 (MMP9) in non-small-cell lung cancer (NSCLC) was evaluated. BMI1 and MMP9 expression in tumors from 132 surgical NSCLC patients [squamous cell carcinoma (SCC), n=79; and adenocarcinoma (AD), n=53] was evaluated by immunohistochemistry...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27899982/expression-and-significance-of-sox2-in-non-small-cell-lung-carcinoma
#14
Jie Ying, Chao Shi, Chuan-Sheng Li, Li-Ping Hu, Wei-Dong Zhang
The aim of the present study was to examine the expression and clinical significance of SOX2 in non-small cell lung carcinoma (NSCLC). Immunohistochemistry was used to detect the expression level of SOX2 in 127 cases of NSCLC. The Chi-square test was used to analyze the association of SOX2 expression and clinicopathological factors in NSCLC and para-carcinoma tissues (2.5%). The Kaplan-Meier method was applied to plot the survival curve, and the log-rank test and COX multiple regression model were applied to determine survival...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27899694/non-small-cell-carcinoma-of-the-lung-with-osteoclast-like-giant-cells
#15
Hans Helmut Dahm
Carcinomas of the lung with benign osteoclast-like giant cells are rare. A literature search showed only 8 previously reported examples. These tumors resemble a giant cell tumor of bone. Many of these tumors, which occur in most epithelium-containing organs, are composed of an undifferentiated, sarcomatoid component that contains benign osteoclast-like giant cells and a conventional carcinoma. In some tumors the epithelial origin may be revealed by immunohistochemistry only; others lack any evidence of an epithelial component...
November 29, 2016: International Journal of Surgical Pathology
https://www.readbyqxmd.com/read/27895920/pd1-pd-l1-inhibition-as-a-potential-radiosensitizer-in-head-and-neck-squamous-cell-carcinoma-a-case-report
#16
Misako Nagasaka, Mark Zaki, Harold Kim, S Naweed Raza, George Yoo, Ho-Sheng Lin, Ammar Sukari
BACKGROUND: Immunotherapy targeting the checkpoint PD1 (programmed cell death protein 1) or PDL1 (programmed death ligand 1) has led to advances in the treatment of melanoma and non-small cell lung cancer (NSCLC). The use of such therapies has also been introduced into the treatment of other malignancies, including head and neck cancer. The combined effects of checkpoint inhibitors and anti-PD1(L1) antibodies and radiation therapy have not yet been sufficiently investigated. CASE PRESENTATION: We report a case of locally relapsed non-resectable oral cavity squamous cell carcinoma, with excellent local control after pembrolizumab (MK3475) followed by radiotherapy...
2016: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/27895756/role-of-microrna-4458-in-patients-with-non-small-cell-lung-cancer
#17
Lidao Bao, Linlin Wang, Guomin Wei, Yuehong Wang, Gerile Wuyun, Agula Bo
Incidence and progression of non-small-cell lung cancer (NSCLC) is a multi-factor, multi-step process. The present study investigated the association between the expression level of microRNA (miR)-4458 in NSCLC and paracarcinoma liver tissues and survival rates, and studied the biological functions of miR-4458 at the cellular and protein level. NSCLC and paracarcinoma tissues were sequenced using a miR expression chip. The association between miR-4458 expression and tumor-node-metastasis staging, total survival rate and relapse-free survival rate was analyzed...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27893446/stability-of-radiomic-features-in-ct-perfusion-maps
#18
M Bogowicz, O Riesterer, R A Bundschuh, P Veit-Haibach, M Hüllner, G Studer, S Stieb, S Glatz, M Pruschy, M Guckenberger, S Tanadini-Lang
This study aimed to identify a set of stable radiomic parameters in CT perfusion (CTP) maps with respect to CTP calculation factors and image discretization, as an input for future prognostic models for local tumor response to chemo-radiotherapy. Pre-treatment CTP images of eleven patients with oropharyngeal carcinoma and eleven patients with non-small cell lung cancer (NSCLC) were analyzed. 315 radiomic parameters were studied per perfusion map (blood volume, blood flow and mean transit time). Radiomics robustness was investigated regarding the potentially standardizable (image discretization method, Hounsfield unit (HU) threshold, voxel size and temporal resolution) and non-standardizable (artery contouring and noise threshold) perfusion calculation factors using the intraclass correlation (ICC)...
December 21, 2016: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/27893417/genetic-and-epigenetic-silencing-of-mircorna-506-3p-enhances-cotl1-oncogene-expression-to-foster-non-small-lung-cancer-progression
#19
Shanqi Guo, Peiying Yang, Xingkang Jiang, Xiaojiang Li, Yuanyuan Wang, Xin Zhang, Binxu Sun, Yao Zhang, Yingjie Jia
Although previous studies suggested that microRNA-506-3p (miR-506-3p) was frequently downregulated, and functioned as a tumor suppressor in several cancers, the biological role and intrinsic regulatory mechanisms of miR-506-3p in non-small cell lung cancer (NSCLC) remain elusive. The present study found miR-506-3p expression was downregulated in advanced NSCLC tissues and cell lines. The expression of miR-506-3p in NSCLC was inversely correlated with larger tumor size, advanced TNM stage and lymph node metastasis...
November 22, 2016: Oncotarget
https://www.readbyqxmd.com/read/27892773/real-world-data-on-nivolumab-treatment-of-non-small-cell-lung-cancer
#20
O T Brustugun, M Sprauten, Å Helland
BACKGROUND: Checkpoint inhibitors have proven effectiveness in clinical trials for non-small cell lung cancer (NSCLC) patients, but if this is congruent with routine patient care is discussed. We present real-world experience with the PD1-inhibitor nivolumab in NSCLC. PATIENTS AND METHODS: Patients with NSCLC were considered eligible for nivolumab treatment after one or more lines of chemotherapy, and when in reasonable performance status (PS) [Eastern Cooperative Oncology Group (ECOG) < 3]...
November 28, 2016: Acta Oncologica
keyword
keyword
117219
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"